Chronic Iron Overload. Desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. Long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. The drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. Desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. Acute iron poisoning: Desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, suction and maintenance of a clear airway, control of shock with intravenous fluids, blood, oxygen and vasopressor and correction of acidosis.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store below 25 degrees Celsius
Protect from Light
Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to cream powder or lyophilised plug.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Chronic Iron Overload. Desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. Long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. The drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. Desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. Acute iron poisoning: Desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, suction and maintenance of a clear airway, control of shock with intravenous fluids, blood, oxygen and vasopressor and correction of acidosis.
How to take it
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Store below 25 degrees Celsius
Protect from Light
Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to cream coloured powder or lyophilised plug.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
Support for this browser is being discontinued
Support for this browser is being discontinued for this site
Internet Explorer 11 and lower
We currently support Microsoft Edge, Chrome, Firefox and Safari. For more information, please visit the links below:
